Clinical Trial Update: Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ATYR1940 for safety and biological activity in LGMD2B and FSHD has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy
• Limb-girdle Muscular Dystrophy Type 2b

Drugs mentioned

• ATYR1940

Snippet

Sponsor: aTyr Pharma, Inc. | Conditions: Limb-Girdle Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-10-19